166 patents
Page 2 of 9
Utility
Methods and Compositions for Inhibiting CD32B Expressing Cells In IGG4-RELATED Diseases
20 Jul 23
The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Filed: 11 Aug 22
Utility
BISPECIFIC HETERODIMERIC FUSION PROTEINS CONTAINING IL-15 - IL-15Ralpha Fc-FUSION PROTEINS AND IMMUNE CHECKPOINT ANTIBODY FRAGMENTS
13 Jul 23
The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Filed: 13 Dec 22
Utility
IL-12 heterodimeric Fc-fusion proteins
23 May 23
The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same.
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
Filed: 11 Aug 22
Utility
IL15/IL15R Alpha Heterodimeric Fc-fusion Proteins for the Treatment of Cancer
18 May 23
The present disclosure provides methods of treating cancer by administering a heterodimeric protein comprising a first monomer comprising an IL15 protein-Fc domain fusion and a second monomer comprising an IL15Rα protein-Fc domain fusion.
Alexander Joachim Paul Ungewickell, Vittal Shivva, Rajbharan Yadav
Filed: 22 Jul 22
Utility
Bispecific Antibodies That Bind to B7H3 and NKG2D
18 May 23
Provided herein are bispecific antibodies that bind to B7H3 and NKG2D (e.g., antibodies having Fab-scFv-Fc, Fab2-scFv-Fc, mAb-scFv and stackFab2-scFv-Fc formats) or antigen binding fragments thereof.
Katrina Bykova, Matthew Faber, Matthew Bernett, Tian Zhang, Erik Pong, Kendra Avery, John Desjarlais
Filed: 7 Nov 22
Utility
IL-18-FC Fusion Proteins
11 May 23
Provided herein are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain.
Alex Nisthal, John Desjarlais, Gregory Moore, Sung-Hyung Lee
Filed: 26 Jul 22
Utility
Bispecific Binding Agents Binding to CLDN18.2 and CD3
4 May 23
The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
Matthew BERNETT, Alex NISTHAL, Gregory MOORE
Filed: 6 Dec 22
Utility
Methods of Treating Neurological Diseases
27 Apr 23
The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.
David Szymkowski, Malu Tansey, Lesley Probert
Filed: 20 Jun 22
Utility
Heterodimeric proteins
25 Apr 23
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Filed: 1 Jul 20
Utility
Heterodimeric antibodies that bind CD3 and PSMA
11 Apr 23
The present invention is directed to heterodimeric antibodies that bind CD3 and PSMA.
Gregory Moore, John Desjarlais, Seung Chu
Filed: 7 Dec 16
Utility
Optimized antibodies that target CD19
4 Apr 23
The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody.
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Filed: 1 Apr 20
Utility
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
4 Apr 23
The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
Filed: 20 Dec 19
Utility
Trispecific Antibodies
23 Mar 23
Provided herein are trispecific antibodies that include a) a first monomer, b) a second monomer, and c) a light chain.
Gregory Moore, John Desjarlais, Seung Chu, Sung-Hyung Lee
Filed: 22 Jul 22
Utility
Treatment with a Bispecific Antibody That Binds CTLA4 and PD1
9 Mar 23
Provided herein, in certain aspects, are methods of treating a cancer in a subject, comprising administering a bispecific anti-CTLA4×anti-PD1 antibody to the subject.
Barbara HICKINGBOTTOM, Paul FOSTER, Raphael CLYNES, Ying DING, Lei BAO, Catherine AVERSA-FLEENER
Filed: 5 Aug 22
Utility
Anti-CD28 compositions
28 Feb 23
Provided herein are novel anti-CD28×anti-B7H3 (also referred to as “αCD28×αB7H3”) heterodimeric bispecific antibodies and methods of using such antibodies for the treatment of cancers.
John R. Desjarlais, Gregory Moore, Michael Hedvat, Juan Diaz, Veronica Gusti Zeng
Filed: 21 Dec 21
Utility
Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE
23 Feb 23
The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life.
Gregory Alan Lazar
Filed: 23 May 22
Utility
PD-1 Targeted IL-15/IL-15RALPHA FC Fusion Proteins and Uses In Combination Therapies Thereof
23 Feb 23
The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
Filed: 2 Jun 22
Utility
Heterodimeric Proteins
23 Feb 23
The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein.
Gregory Moore, Rumana Rashid, John Desjarlais
Filed: 23 Mar 22
Utility
Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
21 Feb 23
The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Filed: 17 Dec 19
Utility
Dosing of a Bispecific Antibody That Binds CD20 and CD3
16 Feb 23
Provided herein, in certain aspects, are methods for the treatment of a CD20-expressing cancer in a human subject, comprising administration of a bispecific anti-CD20×anti-CD3 antibody.
David LIEBOWITZ
Filed: 3 Jun 22